Qynapse is a medical technology company, spin-off of the renowned CATI
consortium of neuroimaging research laboratories.
Headquartered in Paris, Qynapse provides a cloud-based solution for pharmaceutical companies and healthcare providers to support the diagnosis, prognosis and drug efficacy measurement for central nervous system diseases (such as dementia, multiple sclerosis, Parkinson’s and ischemic stroke).
Qynapse is ISO 13485:2016-certified.
Clarisse Longo dos Santos, PhD
Head of clinical development
Head of software development
We have developed strategic partnerships to deliver state of the art technology and services for imaging biomarkers analysis and monitoring. Our key technology partners and sponsors include:
Grants and awards: